Under the Cell and Gene Therapy Access Model, CMS will tie payments for the therapies to their effectiveness in improving health outcomes for Medicaid recipients, according to a Dec. 4 news release from the agency.
The program aims to increase access to these treatments, reduce healthcare costs and improve patient outcomes. Sickle cell disease affects more than 100,000 people in the U.S., with more than half of those who are enrolled in Medicaid.
The model will launch in January 2025, allowing states to participate between January 2025 and January 2026.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.